Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Trading Arrangement: Trading Arrangement [Axis] Maximum Maximum [Member] Statistical Measurement [Domain] Statistical Measurement [Domain] Roche Collaboration and License Agreement Roche Collaboration and License Agreement [Member] Roche Collaboration and License Agreement Title of 12(b) Security Title of 12(b) Security Debt Securities, Available-for-Sale [Table] Debt Securities, Available-for-Sale [Table] Document Fiscal Year Focus Document Fiscal Year Focus Vutrisiran Vutrisiran [Member] Vutrisiran Adjustment to Compensation, Amount Adjustment to Compensation Amount Financial Instrument [Axis] Financial Instrument [Axis] Roche Technology Transfer Obligation Technology Transfer Obligation [Member] Technology Transfer Obligation Segment Reporting [Abstract] Common stock, $0.01 par value per share, 250,000 shares authorized; 133,875 shares issued and outstanding as of September 30, 2026; 132,376 shares issued and outstanding as of December 31, 2025 Common Stock, Value, Issued Depreciation and amortization Depreciation, Amortization and Accretion, Net Loss contingencies accrued Loss Contingency Accrual Line of Credit Line of Credit [Member] Restatement Determination Date Restatement Determination Date Measurement Frequency Measurement Frequency [Axis] Roche Roche [Member] Roche Debt instrument, conversion price (in dollars per share) Debt Instrument, Convertible, Conversion Price Amendment Flag Amendment Flag Clinical research and outside services Clinical Research and Outside Services [Member] Clinical Research and Outside Services Current liabilities: Liabilities, Current [Abstract] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Occupancy and all other costs Occupancy and All Other Costs [Member] Occupancy and All Other Costs Amount received Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances Long-term inventory Inventory, Noncurrent Other comprehensive (loss) income: Other Comprehensive Income (Loss), Net of Tax [Abstract] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Entity Address, State or Province Entity Address, State or Province Foreign currency translation (losses) gains Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent PEO Total Compensation Amount PEO Total Compensation Amount Royalty rate Royalty Rate Potential maximum royalty percentage that will received for sales completed by collaboration partner. Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Financial assets Assets, Fair Value Disclosure [Abstract] Sinking fund payment Debt Instrument, Sinking Fund Payment Weighted-average common shares - basic (in shares) Weighted Average Number of Shares Outstanding, Basic Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Arrangements and Non-arrangement Transactions Collaborative Arrangement and Arrangement Other than Collaborative [Domain] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] Number of Reportable Segments Number of Reportable Segments Total current liabilities Liabilities, Current Convertible debt, net of current portion Convertible Debt, Noncurrent Statements of Comprehensive Income Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Entity Address, City or Town Entity Address, City or Town Schedule of Balances and Activity in Each Product Revenue Allowance and Reserve Category Summary Of Product Revenue Allowance And Reserve Categories Table [Table Text Block] Summary Of Product Revenue Allowance And Reserve Categories Table Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Consulting and professional services Consulting and Professional Services [Member] Consulting and Professional Services Vutrisiran and ALN-AGT Vutrisiran and Zilebesiran [Member] Vutrisiran and Zilebesiran Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Fixed consideration Fixed Consideration Fixed Consideration Net product revenues Product [Member] Consideration received Collaborative Arrangement, Consideration Received Collaborative Arrangement, Consideration Received Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Development milestone payable Collaborative Arrangement, Milestone Payable Collaborative Arrangement, Milestone Payable Debt Conversion Terms Two Debt Conversion Terms Two [Member] Debt Conversion Terms Two AMVUTTRA Amvuttra [Member] Amvuttra Significant Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Other (expense) income: Nonoperating Income (Expense) [Abstract] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Aggregate principal amount Line of Credit Facility, Maximum Borrowing Capacity Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Loss related to convertible debt Loss related to convertible debt Induced Conversion of Convertible Debt Expense License License [Member] Liability Related To The Sale Of Future Royalties [Table] Liability Related To The Sale Of Future Royalties [Table] Liability Related To The Sale Of Future Royalties Table United States UNITED STATES Liabilities related to the sale of future royalties and development funding, net of current portion Royalty And Development Funding Liability, Noncurrent Royalty And Development Funding Liability, Noncurrent Capitalized stock-based compensation costs Share-Based Payment Arrangement, Amount Capitalized Schedule of Long-Term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] C5 License Obligation C5 License Obligation [Member] C5 license obligation. Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Capital expenditures included in accounts payable and accrued expenses Capital Expenditures Incurred but Not yet Paid Deferred revenue Increase (Decrease) in Contract with Customer, Liability Schedule of Expenses by Segment Segment Reporting [Table Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Total other comprehensive (loss) income Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Schedule of Fair Value, Liabilities Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Long term debt outstanding Long-Term Debt Supplemental disclosure of noncash investing activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] Document Period End Date Document Period End Date Changes in operating assets and liabilities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Collaborative arrangement, royalties and commercial milestones acquired by collaborator, percent Collaborative Arrangement, Royalties And Commercial Milestones Acquired By Collaborator, Percent Collaborative Arrangement, Royalties Acquired By Collaborator, Percent Transaction price Transaction Price Transaction Price Net cash (used in) provided by investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Aggregate principal amount Debt Instrument, Face Amount Operating costs and expenses: Costs and Expenses [Abstract] Security Exchange Name Security Exchange Name Effective interest rate (as percent) Effective interest rate Debt Instrument, Interest Rate, Effective Percentage Net income, for use in diluted income per share Net Income (Loss) Attributable to Parent, Diluted Valuation allowance, deferred tax asset, increase (decrease), amount Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Total TTR TTR [Member] TTR Proceeds from liabilities related to the sale of future royalties and development funding Proceeds From Sale Of Royalties Interest Proceeds From Sale Of Royalties Interest Issuance of common stock under equity plans Shares Issued, Value, Share-Based Payment Arrangement, before Forfeiture Funding At Program Initiation Funding At Program Initiation [Member] Funding at program initiation. Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Shell Company Entity Shell Company Maximum percentage of royalty payments Percentage Of Maximum Royalty Payments Percentage of maximum royalty payments. Operating lease liabilities Operating Lease, Liability, Current Obligations Obligations [Member] Royalties payable, term (in years) Collaborative Arrangement, Royalties Payable, Term Collaborative Arrangement, Royalties Payable, Term NET INCOME (LOSS) PER COMMON SHARE Earnings Per Share [Text Block] Proceeds from maturity of restricted and other investments Proceeds from Sale of Restricted Investments Name Outstanding Recovery, Individual Name Earnings Per Share [Abstract] Earnings Per Share [Abstract] Sales and maturities of marketable securities Proceeds from Sale and Maturity of Marketable Securities Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Debt Conversion Terms Three Debt Conversion Terms Three [Member] Debt Conversion Terms Three Document Fiscal Period Focus Document Fiscal Period Focus Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Total liabilities Liabilities Trading Symbol Trading Symbol Total inventory Inventory, Current And Noncurrent Inventory, Current And Noncurrent Geographical Geographical [Domain] Number of marketed products Number Of Products With Marketing Approval Number Of Products With Marketing Approval Purchases of property, plant and equipment Payments to Acquire Property, Plant, and Equipment Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Tolga Tanguler [Member] Tolga Tanguler Cap price (in dollars per share) Option Indexed to Issuer's Equity, Strike Price Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Fair value of liability Royalty Liability, Fair Value Royalty Liability, Fair Value Company Selected Measure Name Company Selected Measure Name Purchases of marketable securities Payments to Acquire Debt Securities, Available-for-Sale Revolving Credit Agreement Revolving Credit Agreement [Member] Revolving Credit Agreement 2022 Capped Call Transactions 2022 Capped Call Transactions [Member] 2022 Capped Call Transactions Amounts reclassified from accumulated other comprehensive loss Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent Blackstone Life Sciences Blackstone Life Sciences [Member] Blackstone Life Sciences Income Tax Disclosure [Abstract] Provision related to current year sales Valuation Allowances And Reserves Provision Related To Current Period Sales Valuation Allowances And Reserves Provision Related To Current Period Sales Purchase price Payments to Acquire Other Investments Defined Benefit Pension Plans, Net of Tax Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Long term debt outstanding Long-Term Debt, Gross Credit Facility [Domain] Credit Facility [Domain] Asset Class [Domain] Asset Class [Domain] Related Party Transactions [Abstract] Cash flows from operating activities: Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Compensation Amount Outstanding Recovery Compensation Amount Individual: Individual [Axis] Roche Development Services Obligation Development Services Obligation [Member] Development Services Obligation Weighted-average common shares - diluted (in shares) Weighted-average common shares - diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Debt Instrument, Convertible Terms of Conversion [Axis] Debt Instrument, Convertible Terms of Conversion [Axis] Debt Instrument, Convertible Terms of Conversion Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Entity Emerging Growth Company Entity Emerging Growth Company Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Payments Royalty Liability, Payments Royalty Liability, Payments Research and Development Arrangement, Contract to Perform for Others, Type Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Commercial paper Commercial Paper [Member] U.S. treasury securities US Treasury Securities [Member] Type of Arrangement and Non-arrangement Transactions Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Royalty and development funding liability, fair value Royalty And Development Funding Liability, Fair Value Royalty And Development Funding Liability, Fair Value Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Loss on Investment in Joint Venture Accumulated Loss On Investment In Joint Venture [Member] Accumulated loss on investment in joint venture. Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Potential proceeds from collaboration arrangement Potential Proceeds From Collaboration Arrangement Potential proceeds from collaboration arrangement. Restricted investments Restricted Investments, Noncurrent Award Timing Predetermined Award Timing Predetermined [Flag] Issuance of letters of credit Letters of Credit Outstanding, Amount Schedule of Available-for-sale Securities [Line Items] Debt Securities, Available-for-Sale [Line Items] Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Funding At Lead Candidate Identification Funding At Lead Candidate Identification [Member] Funding at lead candidate identification. Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Quoted Prices in Active Markets (Level 1) Fair Value, Inputs, Level 1 [Member] Selling, General and Administrative Expense [Axis] Selling, General and Administrative Expense [Axis] Selling, General and Administrative Expense Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Debt instrument conversion ratio Debt Instrument, Convertible, Conversion Ratio Options, RSUs, and ESPP (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Cap price (in dollars per share) Derivative, Cap Price All Executive Categories All Executive Categories [Member] Purchases of capped calls related to convertible senior notes Purchases of capped calls related to 0.00% Convertible Senior Notes due 2028 Payment For Option Indexed To Equity Purchases Of Capped Calls Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Number of commercialized products Number Of Commercialized Products Number Of Commercialized Products Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Number of quarterly payments Collaborative Arrangement, Fixed Payment, Number Of Quarterly Payments Collaborative Arrangement, Fixed Payment, Number Of Quarterly Payments Fair value of long-term debt Long-Term Debt, Fair Value Additional 2028 Notes Convertible Senior Notes Due 2028, Additional Amount [Member] Convertible Senior Notes Due 2028, Additional Amount Collaboration agreement, right to terminate, written advance notice period Collaboration Agreement, Right To Terminate, Written Advance Notice Period Collaboration Agreement, Right To Terminate, Written Advance Notice Period Antidilutive Securities [Axis] Antidilutive Securities [Axis] Scenario [Domain] Scenario [Domain] Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Liquidity Liquidity Policy [Policy Text Block] Liquidity. Schedule of Royalty Liability Schedule Of Royalty Liability [Table Text Block] Schedule Of Royalty Liability Maximum royalties and commercial milestone payments upon potential product sale Maximum Royalties And Commercial Milestone Payments Upon Potential Product Sale Maximum royalties and commercial milestone payments upon potential product sale. Schedule of Basic and Diluted Net Income (Loss) Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] 2028 Notes Convertible Senior Notes Due 2028 [Member] 2028 Notes Debt Disclosure [Abstract] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Royalty revenue Royalty [Member] SEGMENT INFORMATION Segment Reporting [Text Block] Outstanding borrowings Long-Term Line of Credit Minimum Minimum [Member] Net revenues from collaborations Collaborations Collaborations [Member] Collaborations Expiration Date Trading Arrangement Expiration Date HELIOS-B Phase 3 Clinical Trial HELIOS-B Phase 3 Clinical Trial [Member] HELIOS-B Phase 3 Clinical Trial Schedule of Deferred Revenue Activity Disaggregation of Revenue [Table Text Block] Cumulative Effect, Period of Adoption, Adjustment Cumulative Effect, Period of Adoption, Adjustment [Member] Effect of exchange rate changes on cash, cash equivalents and restricted cash Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Income Statement Location Location, Statement of Income, Balance [Axis] Restricted cash (money market funds) Restricted Cash and Cash Equivalent Blackstone Group Inc. Blackstone Group Inc. [Member] Blackstone Group Inc. Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Cash equivalents Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Regeneron Pharmaceuticals Regeneron Pharmaceuticals Incorporation [Member] Regeneron Pharmaceuticals, Incorporation. Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Rest of World Non-US Or Europe [Member] Non-US Or Europe Other license programs Other License Programs [Member] Other License Programs Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Convertible Senior Notes Due 2027 Convertible Senior Notes Due 2027 [Member] Convertible Senior Notes Due 2027 Common stock, shares authorized (in shares) Common Stock, Shares Authorized Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Royalties payable, percent Collaborative Arrangement, Royalties Payable, Percent Collaborative Arrangement, Royalties Payable, Percent Exercise Price Award Exercise Price Cash flows from investing activities: Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Zilebesrian Zilebesrian [Member] Zilebesrian Recurring Fair Value, Recurring [Member] Segment Reporting [Line Items] Segment Reporting [Line Items] Expected royalty interest payments Expected Royalty Interest Payments Expected Royalty Interest Payments Document Quarterly Report Document Quarterly Report Option Indexed to Issuer's Equity, Type [Axis] Option Indexed to Issuer's Equity, Type [Axis] C5 Monotherapy Obligation C5 Monotherapy Obligation [Member] C5 Co-Co obligation. Non-cash interest expense on liabilities related to the sale of future royalties and development funding Non-Cash Interest Expense On Sale Of Future Royalties Non-Cash Interest Expense On Sale Of Future Royalties Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Segments [Domain] Segments [Domain] Upfront payment Collaborative Arrangement, Upfront Payment Collaborative Arrangement, Upfront Payment Accounting Standards Update [Extensible Enumeration] Accounting Standards Update [Extensible Enumeration] Europe Europe [Member] CONVERTIBLE DEBT AND OTHER FINANCING Debt Disclosure [Text Block] Scenario [Axis] Scenario [Axis] Repayments of long-term debt Repayments of Long-Term Debt OXLUMO OXLUMO [Member] OXLUMO Debt issuance costs Debt Issuance Costs, Net Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Equity Component [Domain] Equity Component [Domain] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Total operating costs and expenses Costs and Expenses Adoption Date Trading Arrangement Adoption Date Counterparty Name Counterparty Name [Domain] Cost of borrowing Interest rate (as percent) Debt Instrument, Interest Rate, Stated Percentage Total stockholders' equity Beginning balance Ending balance Equity, Attributable to Parent Total other expense, net Nonoperating Income (Expense) ASSETS Assets [Abstract] Title Trading Arrangement, Individual Title Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Accounting Policies [Abstract] Accounting Policies [Abstract] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Insider Trading Policies and Procedures [Line Items] Liabilities related to the sale of future royalties and development funding, net of current portion Beginning balance Ending balance Royalty Liability, Noncurrent Royalty Liability, Noncurrent Other financing activities Proceeds from (Payment for) Other Financing Activity Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Deferred income taxes Deferred Income Tax Expense (Benefit) Selling, general and administrative Total selling, general and administrative expense Selling, General and Administrative Expense OTHER BALANCE SHEET DETAILS Supplemental Balance Sheet Disclosures [Text Block] Letter of Credit Letter of Credit [Member] ALN-AGT Phase 2 Clinical Trial ALN-AGT Phase 2 Clinical Trial [Member] ALN-AGT Phase 2 Clinical Trial COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Number of reporting segments Number of Operating Segments Anti-dilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Schedule of Common Share Equivalents Excluded from the Calculation of Net Loss Per Common Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Entity Central Index Key Entity Central Index Key Number of partnered products Number Of Partnered Products Number Of Partnered Products Additional paid-in capital Additional Paid in Capital, Common Stock All Adjustments to Compensation All Adjustments to Compensation [Member] Other Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Other Item Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Net cash provided by operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Income Statement [Abstract] Income Statement [Abstract] Stockholders' equity: Equity, Attributable to Parent [Abstract] Document Transition Report Document Transition Report Collaboration agreement, initial research term Collaboration Agreement, Initial Research Term Collaboration Agreement, Initial Research Term Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Deferred tax assets Deferred Income Tax Assets, Net Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Schedule of Reconciliation of Cash, Cash Equivalents And Restricted Cash Schedule Of Reconciliation Of Cash Cash Equivalents And Restricted Cash Table [Table Text Block] Statement of reconciliation of cash, cash equivalents and restricted cash. Credit or payments made during the period for current year sales Valuation Allowances And Reserves Sales Credit Payment Current Valuation Allowances And Reserves Sales Credit Payment Current Leverage ratio Debt Instrument, Basis Spread on Variable Rate City Area Code City Area Code Variable Rate [Domain] Variable Rate [Domain] Restricted stock units, inclusive of performance-based restricted stock units Unvested restricted stock units, inclusive of performance-based restricted stock units Restricted Stock [Member] Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] All Individuals All Individuals [Member] Net revenues from collaborations Net revenues from collaborations Collaborative Arrangement [Member] Beginning balance Ending balance SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount Name Forgone Recovery, Individual Name Number of separate programs Number Of Separate Programs Number Of Separate Programs Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Statement [Line Items] Statement [Line Items] Total assets Assets Call Option Call Option [Member] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Convertible debt Convertible Debt [Member] Convertible debt Convertible Debt, Current Maximum funding Collaborative Arrangement, Maximum Funding Collaborative Arrangement, Maximum Funding Defined benefit pension plans, net of tax Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent Interest expense Interest Expense, Nonoperating GIVLAARI GIVLAARI [Member] GIVLAARI STOCK-BASED COMPENSATION Share-Based Payment Arrangement [Text Block] Fixed payment, term (in years) Collaborative Arrangement, Fixed Payment, Term Collaborative Arrangement, Fixed Payment, Term Proceeds from issuance of 0.00% Convertible Senior Notes due 2028, net Proceeds from Convertible Debt Other comprehensive loss before reclassifications OCI, before Reclassifications, Net of Tax, Attributable to Parent NATURE OF BUSINESS Nature of Operations [Text Block] PEO PEO [Member] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] MARKETABLE DEBT SECURITIES Investments In Marketable Debt Securities Disclosure [Text Block] Investments in marketable debt securities disclosure. Total stock-based compensation expense Share-Based Payment Arrangement, Expense Other liabilities Other Liabilities, Noncurrent Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Exercise of common stock options, net of tax withholdings (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Contract with customer liability revenue recognized Contract with Customer, Liability, Revenue Recognized Realized and unrealized loss on marketable equity securities Equity Securities, FV-NI, Gain (Loss) Development costs, percentage responsible Development Costs, Percent Responsible Development Costs, Percent Responsible Royalty Liability Rollforward [Abstract] Royalty Liability Rollforward [Abstract] Royalty Liability Rollforward Accumulated Deficit Retained Earnings [Member] Operating lease liabilities, net of current portion Operating Lease, Liability, Noncurrent Revolving Credit Facility Revolving Credit Facility [Member] Money market funds Money Market Funds [Member] Unrealized Gains (Losses) from Debt Securities AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member] Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Unrealized (losses) gains on marketable securities OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Common stock, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Award Timing Disclosures [Line Items] Foreign Currency Translation Adjustment Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Schedule of Fair Value of Marketable Debt Securities Fair Value, by Balance Sheet Grouping [Table Text Block] Payment of issuance costs for revolving credit agreement Payments of Debt Issuance Costs Corporate notes Corporate Debt Securities [Member] Net income per common share — diluted (in dollars per share) Earnings Per Share, Diluted Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Entity Current Reporting Status Entity Current Reporting Status Net cash provided by (used in) financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Profit and loss sharing percentage Profit and Loss Sharing, Percent Profit and Loss Sharing, Percent Total Shareholder Return Amount Total Shareholder Return Amount Covenant, leverage ratio, minimum Debt Instrument, Covenant, Liquidity Ratio, Minimum Debt Instrument, Covenant, Liquidity Ratio, Minimum Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets LIABILITIES RELATED TO THE SALE OF FUTURE ROYALTIES AND DEVELOPMENT FUNDING Liability Related To The Sale Of Future Royalties And Development Funding [Text Block] Liability Related To The Sale Of Future Royalties And Development Funding Initial 2028 Notes Convertible Senior Notes Due 2028, Initial Amount [Member] Convertible Senior Notes Due 2028, Initial Amount Convertible Senior Notes Due 2027, Additional Amount Convertible Senior Notes Due 2027, Additional Amount [Member] Convertible Senior Notes Due 2027, Additional Amount Research and development Total research and development expense Research and Development Expense Adjustments to reconcile net income to net cash provided by operating activities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] Maximum additional milestone payments to be receive upon achievement of certain criteria Maximum Additional Milestone Payments To Be Receive Upon Achievement Of Certain Criteria Maximum additional milestone payments to be receive upon achievement of certain criteria. Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Share-Based Payment Arrangement [Abstract] Cash flows from financing activities: Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Total revenues Revenue recognized Revenue from Contract with Customer, Excluding Assessed Tax Property, plant and equipment, net Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization Commitment fee on the unused portion of leverage ratio Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Financial Instruments [Domain] Financial Instruments [Domain] Total stock-based compensation charges Share-Based Payment Arrangement, Expensed and Capitalized, Amount Exercise of common stock options, net of tax withholdings Stock Issued During Period, Value, Stock Options Exercised Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Underlying Securities Award Underlying Securities Amount NET PRODUCT REVENUES Revenue from Contract with Customer [Text Block] Regeneron Technology Transfer Obligation Regeneron Technology Transfer Obligation [Member] Regeneron Technology Transfer Obligation Proceeds from exercise of stock options and other types of equity, net Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised Commercial milestones acquired by collaborator, percent Collaborative Arrangement, Commercial Milestones Acquired By Collaborator, Percent Collaborative Arrangement, Commercial Milestones Acquired By Collaborator, Percent Other investing activities Payment for (Proceeds from) Other Investing Activity Inventory Increase (Decrease) in Inventories Global Strategic Collaboration Global Strategic Collaboration [Member] Global strategic collaboration. Segment Reporting [Table] Segment Reporting [Table] Closing costs Royalty Liability, Closing Costs Royalty Liability, Closing Costs Schedule of Marketable Debt Securities Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] Cost of collaborations and royalties Cost Of Collaboration Manufacturing And Royalties Cost Of Collaboration Manufacturing And Royalties Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] All Trading Arrangements All Trading Arrangements [Member] Beginning balance Ending balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Other Performance Measure, Amount Other Performance Measure, Amount Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Income from operations Operating Income (Loss) Remaining performance obligation Revenue, Remaining Performance Obligation, Amount Current Fiscal Year End Date Current Fiscal Year End Date Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Issuance of common stock under equity plans (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture Cumulative Effect, Period of Adoption [Domain] Cumulative Effect, Period of Adoption [Domain] Interest expense Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Interest Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Interest Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Entity File Number Entity File Number Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Single Reportable Segment Single Reportable Segment [Member] Single Reportable Segment Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Common stock, shares issued (in shares) Common Stock, Shares, Issued Measure: Measure [Axis] Finished goods Inventory, Finished Goods, Gross BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION Business Description and Basis of Presentation [Text Block] Marketable debt securities Marketable debt securities Debt Securities, Available-for-Sale, Current Vir Biotechnology, Inc. Vir Biotechnology, Inc. [Member] Vir Biotechnology, Inc. Equity Components [Axis] Equity Components [Axis] Accounts receivable, net Increase (Decrease) in Accounts Receivable Product and Service [Domain] Product and Service [Domain] Cash paid for taxes Income Tax Paid, after Refund Received Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption [Axis] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Entity Interactive Data Current Entity Interactive Data Current Variable Rate [Axis] Variable Rate [Axis] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Debt Conversion Terms One Debt Conversion Terms One [Member] Debt Conversion Terms One Entity Small Business Entity Small Business Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Termination Date Trading Arrangement Termination Date Amount paid Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Initial conversion price, premium, percentage Debt Instrument, Convertible, Premium, Percentage Debt Instrument, Convertible, Premium, Percentage Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] U.S. government-sponsored enterprise securities US Government-sponsored Enterprises Debt Securities [Member] Other assets Other Assets, Noncurrent Document Type Document Type Debt, repurchased Debt Instrument, Repurchased Face Amount Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Loss on extinguishment of debt Gain (Loss) on Extinguishment of Debt Accrued expenses Accrued Liabilities, Current Fair Value as of Grant Date Award Grant Date Fair Value Repayment of 1.00% Convertible Senior Notes due 2027 Repurchase cost including accrued and unpaid interest Repayments of Convertible Debt Debt instrument, redemption price percentage Debt Instrument, Redemption Price, Percentage Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Arrangement Duration Trading Arrangement Duration Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Number of performance obligations Number of Performance Obligations Number of Performance Obligations Local Phone Number Local Phone Number Work in process Inventory, Work in Process, Gross Selling, General and Administrative Expense [Domain] Selling, General and Administrative Expense [Domain] Selling, General and Administrative Expense [Domain] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Registrant Name Entity Registrant Name Income before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Commitments and contingencies (Note 12) Commitments and Contingencies Option Indexed to Issuer's Equity, Type [Domain] Option Indexed to Issuer's Equity, Type [Domain] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Fair Value Total Debt Securities, Available-for-Sale, Including Cash Equivalents Debt Securities, Available-for-Sale, Including Cash Equivalents Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Accounts payable, accrued expenses and other liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Executive Category: Executive Category [Axis] Liability Related To The Sale Of Future Royalties [Line Items] Liability Related To The Sale Of Future Royalties [Line Items] Liability Related To The Sale Of Future Royalties [Line Items] Actual reimbursement of transactional price (as percent) Revenue Recognition, Percentage of Actual Reimbursement Revenue Recognition, Percentage of Actual Reimbursement Counterparty Name Counterparty Name [Axis] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Debt Instrument, Convertible Terms of Conversion [Domain] Debt Instrument, Convertible Terms of Conversion [Domain] Debt Instrument, Convertible Terms of Conversion Chargebacks and Rebates Chargebacks And Rebates [Member] Chargebacks And Rebates Schedule of Fair Value of Assets Measured on a Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Inventory Inventory, Net All Award Types Award Type [Domain] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost, Including Cash Equivalents Debt Securities, Available-for-Sale, Amortized Cost, Including Cash Equivalents Purchase of capped calls related to —% Convertible Senior Notes due 2028 Purchase of capped calls related to —% Convertible Senior Notes due 2028 Adjustments To Additional Paid In Capital, Option Contract Indexed To Equity Adjustments To Additional Paid In Capital, Option Contract Indexed To Equity Supplemental disclosure of cash flows: Supplemental Cash Flow Information [Abstract] Credit or payments made during the period for prior years’ sales Valuation Allowances And Reserves Sales Credit Payment Prior Valuation Allowances And Reserves Sales Credit Payment Prior Share price (in dollars per share) Share Price PEO Name PEO Name Percentage of stock price trigger Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger Geographical Geographical [Axis] Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Entity Tax Identification Number Entity Tax Identification Number ALN-AGT Phase 3 Clinical Trial ALN-AGT Phase 3 Clinical Trial [Member] ALN-AGT Phase 3 Clinical Trial 2022 and 2025 Capped Call Transactions 2022 and 2025 Capped Call Transactions [Member] 2022 and 2025 Capped Call Transactions Schedule of Revenue from Collaborators Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block] Liability Class [Axis] Liability Class [Axis] Cash, cash equivalents and restricted cash, beginning of period Cash, cash equivalents and restricted cash, end of period Total cash, cash equivalents, and restricted cash shown in the condensed consolidated statements of cash flows Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Base Rate Base Rate [Member] Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Non-NEOs Non-NEOs [Member] Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Measurement Frequency [Domain] Measurement Frequency [Domain] Debt Instrument [Axis] Debt Instrument [Axis] Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Debt Conversion Terms Four Debt Conversion Terms Four [Member] Debt Conversion Terms Four Employee stock purchase program Employee Stock [Member] Interest rate Royalty Liability, Interest Rate Royalty Liability, Interest Rate Schedule of Inventory Schedule of Inventory, Current [Table Text Block] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Net income per common share — basic (in dollars per share) Earnings Per Share, Basic Raw materials Inventory, Raw Materials, Gross Deferred revenue Contract liabilities included in deferred revenue Contract with Customer, Liability, Current Total current assets Assets, Current Statistical Measurement [Axis] Statistical Measurement [Axis] Insider Trading Arrangements [Line Items] Adjustment for the elimination of interest expense on the convertible debt Interest On Convertible Debt, Adjustment Interest On Convertible Debt, Adjustment Award Type Award Type [Axis] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Accounts receivable, net Net product revenue-related receivables Receivables included in accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Accumulated deficit Retained Earnings (Accumulated Deficit) Provision related to prior years’ sales Valuation Allowances And Reserves Provision Related To Prior Period Sales Valuation Allowances And Reserves Provision Related To Prior Period Sales Municipal securities Municipal Notes [Member] Product and Service [Axis] Product and Service [Axis] Trading days threshold Debt Instrument, Convertible, Threshold Trading Days Total restricted cash included in other assets Restricted Cash, Noncurrent Repayment of liabilities related to the sale of future royalties and development funding Repayment Of Liabilities Related To The Sale Of Future Royalties And Development Funding Repayment Of Liabilities Related To The Sale Of Future Royalties And Development Funding Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Roche License Obligation License Obligation [Member] License Obligation Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Common Stock Common Stock [Member] Marketable debt securities Debt Securities, Available-for-Sale Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Cover [Abstract] Development Milestone Development Milestone [Member] Development Milestone Premium on capped call transactions Option Indexed to Issuer's Equity, Premium On Stock Price Option Indexed to Issuer's Equity, Premium On Stock Price Equity Awards Adjustments Equity Awards Adjustments [Member] COLLABORATIONS Collaborative Arrangement Disclosure [Text Block] Total liabilities and stockholders' equity Liabilities and Equity Options to purchase common stock, inclusive of performance-based stock options Share-Based Payment Arrangement, Option [Member] Liabilities related to the sale of future royalties and development funding Royalty And Development Funding Liability, Current Royalty And Development Funding Liability, Current Repurchase of 1.00% Convertible Senior Notes due 2027 Adjustments To Additional Paid In Capital, Repurchase Of Convertible Debt Adjustments To Additional Paid In Capital, Repurchase Of Convertible Debt Segments [Axis] Segments [Axis] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Asset Class [Axis] Asset Class [Axis] Tabular List, Table Tabular List [Table Text Block] Compensation and related Compensation and Related [Member] Compensation and Related Schedule of Stock Based Compensation Share-Based Payment Arrangement, Cost by Plan [Table Text Block] Other income (expense), net Other Nonoperating Income (Expense) Convertible debt (in shares) Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities Interest expense Royalty Liability, Interest Expense Including Amortization Of Closing Costs Royalty Liability, Interest Expense Including Amortization Of Closing Costs Name Awards Close in Time to MNPI Disclosures, Individual Name Research And Development Expense [Domain] Research And Development Expense [Domain] Research And Development Expense [Domain] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Total Rare Rare [Member] Rare Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Preferred stock, $0.01 par value per share, 5,000 shares authorized and no shares issued and outstanding as of September 30, 2026 and December 31, 2025 Preferred Stock, Value, Issued Adjustment to Compensation: Adjustment to Compensation [Axis] Collaborative arrangement milestone payments, per collaboration project Collaborative Arrangement Milestone Payments, Per Collaboration Project Collaborative arrangement milestone payments. Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax, Including Cash Equivalents Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax, Including Cash Equivalents Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activity Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Credit Facility [Axis] Credit Facility [Axis] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Total financial assets Assets, Fair Value Disclosure Name Measure Name INCOME TAXES Income Tax Disclosure [Text Block] Purchases of restricted and other investments Payments to Acquire Restricted Investments Accounts payable Accounts Payable, Current Pay vs Performance Disclosure [Line Items] Research And Development Expense [Axis] Research And Development Expense [Axis] Research And Development Expense Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, Before Tax, Including Cash Equivalents Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, Before Tax, Including Cash Equivalents Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Debt Instrument [Line Items] Debt Instrument [Line Items] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Inceptive Nucleics, Inc Inceptive Nucleics, Inc [Member] Inceptive Nucleics, Inc Research Services Obligation Research Services Obligation [Member] Research services obligation. Additional Paid-in Capital Additional Paid-in Capital [Member] Entity Filer Category Entity Filer Category Name Trading Arrangement, Individual Name Cash and cash equivalents Cash and cash equivalents Cash and Cash Equivalent Interest rate (as percent) Debt Instrument, Interest Rate During Period Other Incentives and Allowances Other Incentives And Allowances [Member] Other Incentives And Allowances Designated candidates, period after expiration of initial research term Collaboration Agreement, Designated Candidates, Period After Expiration Of Initial Research Term Collaboration Agreement, Designated Candidates, Period After Expiration Of Initial Research Term Company Selected Measure Amount Company Selected Measure Amount Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] Secured Overnight Financing Rate (SOFR) Secured Overnight Financing Rate (SOFR) [Member] Schedule of Allocated Transaction Price Based on Accounting Guidance Schedule of Allocated Transaction Price [Table Text Block] Schedule of Allocated Transaction Price Entity Address, Address Line Two Entity Address, Address Line Two Current assets: Assets, Current [Abstract] Non-PEO NEO Non-PEO NEO [Member] Entity Address, Address Line One Entity Address, Address Line One Operating lease right-of-use assets obtained in exchange for new operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Benefit from (provision for) income taxes Income Tax Expense (Benefit) Effect of dilutive securities: Dilutive Securities, Effect on Basic Earnings Per Share [Abstract] Number of cardiometabolic programs Number Of Cardiometabolic Programs Number Of Cardiometabolic Programs Research and Development Arrangement, Contract to Perform for Others, Type Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Cost of goods sold Cost of Product and Service Sold SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] Award Timing Method Award Timing Method [Text Block] Other Product and Service, Other [Member] Basis of Presentation and Principles of Consolidation Consolidation, Policy [Policy Text Block] Net increase in cash, cash equivalents and restricted cash Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Forecast Forecast [Member] Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] AOCI Attributable to Parent, Net of Tax [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Net income Net income Net income (loss) Net income, as reported Net Income (Loss) Attributable to Parent Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Other Other Collaborations [Member] Other collaboration. Statement [Table] Statement [Table] Restatement Determination Date: Restatement Determination Date [Axis] Schedule of Changes in Accumulated Other Comprehensive Loss Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Interest income Investment Income, Interest Schedule of Deferred Revenue Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Consecutive trading days threshold Debt Instrument, Convertible, Threshold Consecutive Trading Days Covenant, interest coverage ratio, maximum Debt Instrument, Covenant, Interest Coverage Ratio, Maximum Debt Instrument, Covenant, Interest Coverage Ratio, Maximum Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] ONPATTRO ONPATTRO [Member] ONPATTRO Revenues: Revenues [Abstract] Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Accounting Standards Update 2025-07 [Member]